A proteomic approach to host humoral immune response

白色念珠菌是人类最常见的真菌病原体。它是一种常见的病原体，在医院引起血液感染，估计死亡率为40%。在高危患者中预防性抗真菌药物的使用增加加速了耐药性的发展。迫切需要替代抗真菌治疗。避免抗真菌耐药性的一种有希望的方法是使用基于免疫的疗法。保护 抗C.白色念珠菌热休克蛋白90（Hsp 90）或β-甘露聚糖已显示对实验小鼠中的血源性播散性念珠菌病具有活性。特别是，针对Hsp 90的人类基因重组抗体目前正在对传播性念珠菌病患者进行跨国试验。为了确定潜在的疫苗和保护性抗体，我们建议开发一种C。白念珠菌蛋白微阵列来分析大量侵袭性念珠菌病患者的体液反应。

Candida albicans is the most frequently isolated fungal pathogen of humans. It is a common pathogen that causes bloodstream infection in hospitals, with estimated mortality at 40%. Increased use of prophylactic antifungal drugs in high-risk patients accelerates the development of drug resistance. Alternative antifungal therapies are urgently needed. One promising approach to avoid anti-fungal resistance is to use immune-based therapies. Protective antibodies against C. albicans heat shock protein 90 (Hsp90) or beta-mannan have been shown to be active against hematogenously disseminated candidiasis in experimental mice. In particular, a human genetically recombinant antibody against the Hsp90 is currently in a multinational trial in patients with disseminated candidiasis. To identify potential vaccines and protective antibodies, we propose to develop a C. albicans protein microarray to profile humoral responses in a large number of patients with invasive candidiasis.